Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Pfizer, BioNTech Rise After FDA Approves Covid Boosters for Children

Published 05/17/2022, 02:33 PM
Updated 05/17/2022, 02:55 PM
© Reuters

By Liz Moyer -- Pfizer Inc (NYSE:PFE) shares rose after the Food and Drug Administration approved its Covid-19 booster shot for children aged 5 to 11. 

Pfizer stock rose 0.6% in mid-afternoon trading on Tuesday and BioNTech SE (NASDAQ:BNTX) shares rose 5.5%. Shares of their rival in mRNA vaccines against Covid, Moderna Inc (NASDAQ:MRNA), jumped 3.7%.

The FDA said that the data show the protection provided by two shots fades with time and that a third shot can shore up protection for children. It added that the benefits outweigh the risks. 

Still, parents seem to be holding off on vaccinating this school-aged group. Less than 30% of children 5 to 11 have gotten their primary two doses as of April, according to the Centers for Disease Control and Prevention, which is expected to meet Thursday to sign off on the boosters as well.

The advisory committee on vaccines for the FDA plans to meet in June to review requests from Pfizer and Moderna to approve the Covid vaccines for children under age 5.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.